BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 27482709)

  • 21. Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age.
    Leenen CH; Goverde A; de Bekker-Grob EW; Wagner A; van Lier MG; Spaander MC; Bruno MJ; Tops CM; van den Ouweland AM; Dubbink HJ; Kuipers EJ; Dinjens WN; van Leerdam ME; Steyerberg EW
    Genet Med; 2016 Oct; 18(10):966-73. PubMed ID: 26938782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simplified identification of Lynch syndrome: a prospective, multicenter study.
    Bonnet D; Selves J; Toulas C; Danjoux M; Duffas JP; Portier G; Kirzin S; Ghouti L; Carrère N; Suc B; Alric L; Barange K; Buscail L; Chaubard T; Imani K; Guimbaud R
    Dig Liver Dis; 2012 Jun; 44(6):515-22. PubMed ID: 22480969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness.
    Reyes CM; Allen BA; Terdiman JP; Wilson LS
    Cancer; 2002 Nov; 95(9):1848-56. PubMed ID: 12404277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implication of DNA repair genes in Lynch-like syndrome.
    Xicola RM; Clark JR; Carroll T; Alvikas J; Marwaha P; Regan MR; Lopez-Giraldez F; Choi J; Emmadi R; Alagiozian-Angelova V; Kupfer SS; Ellis NA; Llor X
    Fam Cancer; 2019 Jul; 18(3):331-342. PubMed ID: 30989425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.
    Espenschied CR; LaDuca H; Li S; McFarland R; Gau CL; Hampel H
    J Clin Oncol; 2017 Aug; 35(22):2568-2575. PubMed ID: 28514183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch syndrome.
    van Lier MG; Leenen CH; Wagner A; Ramsoekh D; Dubbink HJ; van den Ouweland AM; Westenend PJ; de Graaf EJ; Wolters LM; Vrijland WW; Kuipers EJ; van Leerdam ME; Steyerberg EW; Dinjens WN;
    J Pathol; 2012 Apr; 226(5):764-74. PubMed ID: 22081473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF V600E mutation analysis simplifies the testing algorithm for Lynch syndrome.
    Jin M; Hampel H; Zhou X; Schunemann L; Yearsley M; Frankel WL
    Am J Clin Pathol; 2013 Aug; 140(2):177-83. PubMed ID: 23897252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome.
    Kang YJ; Killen J; Caruana M; Simms K; Taylor N; Frayling IM; Snowsill T; Huxley N; Coupe VM; Hughes S; Freeman V; Boussioutas A; Trainer AH; Ward RL; Mitchell G; Macrae FA; Canfell K
    Med J Aust; 2020 Feb; 212(2):72-81. PubMed ID: 31595523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Taiwan hospital-based detection of Lynch syndrome distinguishes 2 types of microsatellite instabilities in colorectal cancers.
    Chang SC; Lin PC; Yang SH; Wang HS; Liang WY; Lin JK
    Surgery; 2010 May; 147(5):720-8. PubMed ID: 20045164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening for Lynch syndrome and referral to clinical genetics by selective mismatch repair protein immunohistochemistry testing: an audit and cost analysis.
    Colling R; Church DN; Carmichael J; Murphy L; East J; Risby P; Kerr R; Chetty R; Wang LM
    J Clin Pathol; 2015 Dec; 68(12):1036-9. PubMed ID: 26201544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives.
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2009 Jan; 11(1):35-41. PubMed ID: 19125126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic testing for Lynch syndrome in the province of Ontario.
    Wang M; Aldubayan S; Connor AA; Wong B; Mcnamara K; Khan T; Semotiuk K; Khalouei S; Holter S; Aronson M; Cohen Z; Gallinger S; Charames G; Pollett A; Lerner-Ellis J
    Cancer; 2016 Jun; 122(11):1672-9. PubMed ID: 27019099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Point: justification for Lynch syndrome screening among all patients with newly diagnosed colorectal cancer.
    Hampel H
    J Natl Compr Canc Netw; 2010 May; 8(5):597-601. PubMed ID: 20495086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening.
    Bessa X; Ballesté B; Andreu M; Castells A; Bellosillo B; Balaguer F; Castellví-Bel S; Paya A; Jover R; Alenda C; Titó L; Martinez-Villacampa M; Vilella A; Xicola RM; Pons E; Llor X;
    Clin Gastroenterol Hepatol; 2008 Feb; 6(2):206-14. PubMed ID: 18096441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
    Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R
    Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of paired tumor and germline testing in evaluation of patients with Lynch-like syndrome in a large integrated healthcare setting.
    Carwana H; Hoodfar E; Bergoffen J; Li D
    Fam Cancer; 2021 Jul; 20(3):223-230. PubMed ID: 33215268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effectiveness of screening strategies for Lynch syndrome.
    Barzi A; Sadeghi S; Kattan MW; Meropol NJ
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25794514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study.
    Gausachs M; Mur P; Corral J; Pineda M; González S; Benito L; Menéndez M; Espinàs JA; Brunet J; Iniesta MD; Gruber SB; Lázaro C; Blanco I; Capellá G
    Eur J Hum Genet; 2012 Jul; 20(7):762-8. PubMed ID: 22274583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer.
    Piñol V; Castells A; Andreu M; Castellví-Bel S; Alenda C; Llor X; Xicola RM; Rodríguez-Moranta F; Payá A; Jover R; Bessa X;
    JAMA; 2005 Apr; 293(16):1986-94. PubMed ID: 15855432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implementation of a Systematic Tumor Screening Program for Lynch Syndrome in an Integrated Health Care Setting.
    Clarke EV; Muessig KR; Zepp J; Hunter JE; Syngal S; Acheson LS; Wiesner GL; Peterson SK; Bergen KM; Shuster E; Davis JV; Schneider JL; Kauffman TL; Gilmore MJ; Reiss JA; Rope AF; Cook JE; Goddard KAB
    Fam Cancer; 2019 Jul; 18(3):317-325. PubMed ID: 30729418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.